Investors Asset Management of Georgia Inc. GA ADV lifted its stake in Pfizer Inc. (NYSE:PFE) by 1.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 55,374 shares of the biopharmaceutical company’s stock after acquiring an additional 800 shares during the quarter. Pfizer accounts for 1.4% of Investors Asset Management of Georgia Inc. GA ADV’s investment portfolio, making the stock its 10th largest position. Investors Asset Management of Georgia Inc. GA ADV’s holdings in Pfizer were worth $2,032,000 as of its most recent filing with the SEC.
Several other large investors also recently bought and sold shares of the stock. Corbett Road Capital Management LLC acquired a new position in Pfizer in the 2nd quarter valued at about $25,000. Reitz Capital Advisors LLC purchased a new position in shares of Pfizer in the second quarter valued at approximately $29,000. Disciplined Investments LLC boosted its stake in shares of Pfizer by 43.3% in the first quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 347 shares during the period. Rocky Mountain Advisers LLC grew its holdings in shares of Pfizer by 847.5% in the second quarter. Rocky Mountain Advisers LLC now owns 1,118 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 1,000 shares in the last quarter. Finally, JJJ Advisors Inc. purchased a new stake in Pfizer during the 2nd quarter worth approximately $44,000. 69.08% of the stock is owned by hedge funds and other institutional investors.
PFE has been the subject of several research reports. Mizuho restated a “buy” rating and issued a $43.00 price target on shares of Pfizer in a research note on Tuesday, September 15th. UBS Group boosted their target price on Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 29th. SVB Leerink upped their price target on Pfizer from $39.00 to $42.00 and gave the stock a “market perform” rating in a report on Wednesday, July 29th. Atlantic Securities cut Pfizer from an “overweight” rating to a “neutral” rating and decreased their price objective for the company from $44.00 to $39.00 in a research note on Monday, October 12th. Finally, Berenberg Bank began coverage on shares of Pfizer in a research note on Tuesday, September 29th. They set a “hold” rating and a $38.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $39.64.
In other news, Director Ronald E. Blaylock bought 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was purchased at an average cost of $38.55 per share, with a total value of $501,150.00. Following the transaction, the director now directly owns 4,000 shares in the company, valued at $154,200. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.08% of the stock is currently owned by insiders.
Shares of Pfizer stock opened at $37.95 on Friday. The company has a quick ratio of 1.16, a current ratio of 1.42 and a debt-to-equity ratio of 0.78. Pfizer Inc. has a 52 week low of $27.88 and a 52 week high of $40.97. The firm’s 50 day moving average is $36.59 and its two-hundred day moving average is $36.32. The firm has a market capitalization of $210.88 billion, a P/E ratio of 15.06, a P/E/G ratio of 2.91 and a beta of 0.67.
Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm had revenue of $11.80 billion for the quarter, compared to the consensus estimate of $11.55 billion. During the same period last year, the firm posted $0.80 EPS. The company’s revenue was down 11.0% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be given a dividend of $0.38 per share. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.01%. The ex-dividend date is Thursday, November 5th. Pfizer’s dividend payout ratio (DPR) is currently 51.53%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Story: Insider Trading
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.